The recent push for drug pricing controls in the US has pharma giants and consumers alike scratching their heads. One area facing potential fallout is direct-to-consumer (DTC) advertising, those glossy commercials and magazine spreads that pitch pills for everything from heartburn to depression. But will a squeeze on pharmaceutical profits spell the end of DTC as we know it?